Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of atezolizumab combined with stereotactic ablative radiotherapy (SABR) in metastatic tumours
2015-005464-42Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in metastatic renal cell carcinoma (mRCC) and Nonhematologic neoplasms, sponsored by Gustave Roussy. Primary endpoint: 1-year progression-free survival rate. Started Jun 2016; status: active.
02
Drugs
atezolizumab
03
Conditions
metastatic renal cell carcinoma (mRCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2015-005464-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005464-42.